Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Insights into Praziquantel metabolism and potential enantiomeric CYP-mediated drug-drug interaction.

Vendrell-Navarro G, Scheible H, Lignet F, Burt H, Luepfert C, Marx A, Abla N, Swart P, Perrin D.

Drug Metab Dispos. 2020 Mar 19. pii: dmd.119.089888. doi: 10.1124/dmd.119.089888. [Epub ahead of print]

2.

An in vitro toolbox to accelerate anti-malarial drug discovery and development.

Charman SA, Andreu A, Barker H, Blundell S, Campbell A, Campbell M, Chen G, Chiu FCK, Crighton E, Katneni K, Morizzi J, Patil R, Pham T, Ryan E, Saunders J, Shackleford DM, White KL, Almond L, Dickins M, Smith DA, Moehrle JJ, Burrows JN, Abla N.

Malar J. 2020 Jan 2;19(1):1. doi: 10.1186/s12936-019-3075-5.

3.

Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds.

Katneni K, Pham T, Saunders J, Chen G, Patil R, White KL, Abla N, Chiu FCK, Shackleford DM, Charman SA.

Pharm Res. 2018 Sep 17;35(11):210. doi: 10.1007/s11095-018-2493-3.

4.

Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale.

Bonate PL, Wang T, Passier P, Bagchus W, Burt H, Lüpfert C, Abla N, Kovac J, Keiser J.

J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):747-762. doi: 10.1007/s10928-018-9601-1. Epub 2018 Sep 14.

5.

Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol.

Abla N, Bashyam S, Charman SA, Greco B, Hewitt P, Jiménez-Díaz MB, Katneni K, Kubas H, Picard D, Sambandan Y, Sanz L, Smith D, Wang T, Willis P, Wittlin S, Spangenberg T.

ACS Med Chem Lett. 2017 Nov 28;8(12):1304-1308. doi: 10.1021/acsmedchemlett.7b00391. eCollection 2017 Dec 14.

6.

Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.

Abla N, Keiser J, Vargas M, Reimers N, Haas H, Spangenberg T.

PLoS Negl Trop Dis. 2017 Sep 21;11(9):e0005942. doi: 10.1371/journal.pntd.0005942. eCollection 2017 Sep.

7.

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.

Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Alemán Resto Y, Alsibaee A, Alzualde A, Andrews KT, Avery SV, Avery VM, Ayong L, Baker M, Baker S, Ben Mamoun C, Bhatia S, Bickle Q, Bounaadja L, Bowling T, Bosch J, Boucher LE, Boyom FF, Brea J, Brennan M, Burton A, Caffrey CR, Camarda G, Carrasquilla M, Carter D, Belen Cassera M, Chih-Chien Cheng K, Chindaudomsate W, Chubb A, Colon BL, Colón-López DD, Corbett Y, Crowther GJ, Cowan N, D'Alessandro S, Le Dang N, Delves M, DeRisi JL, Du AY, Duffy S, Abd El-Salam El-Sayed S, Ferdig MT, Fernández Robledo JA, Fidock DA, Florent I, Fokou PV, Galstian A, Gamo FJ, Gokool S, Gold B, Golub T, Goldgof GM, Guha R, Guiguemde WA, Gural N, Guy RK, Hansen MA, Hanson KK, Hemphill A, Hooft van Huijsduijnen R, Horii T, Horrocks P, Hughes TB, Huston C, Igarashi I, Ingram-Sieber K, Itoe MA, Jadhav A, Naranuntarat Jensen A, Jensen LT, Jiang RH, Kaiser A, Keiser J, Ketas T, Kicka S, Kim S, Kirk K, Kumar VP, Kyle DE, Lafuente MJ, Landfear S, Lee N, Lee S, Lehane AM, Li F, Little D, Liu L, Llinás M, Loza MI, Lubar A, Lucantoni L, Lucet I, Maes L, Mancama D, Mansour NR, March S, McGowan S, Medina Vera I, Meister S, Mercer L, Mestres J, Mfopa AN, Misra RN, Moon S, Moore JP, Morais Rodrigues da Costa F, Müller J, Muriana A, Nakazawa Hewitt S, Nare B, Nathan C, Narraidoo N, Nawaratna S, Ojo KK, Ortiz D, Panic G, Papadatos G, Parapini S, Patra K, Pham N, Prats S, Plouffe DM, Poulsen SA, Pradhan A, Quevedo C, Quinn RJ, Rice CA, Abdo Rizk M, Ruecker A, St Onge R, Salgado Ferreira R, Samra J, Robinett NG, Schlecht U, Schmitt M, Silva Villela F, Silvestrini F, Sinden R, Smith DA, Soldati T, Spitzmüller A, Stamm SM, Sullivan DJ, Sullivan W, Suresh S, Suzuki BM, Suzuki Y, Swamidass SJ, Taramelli D, Tchokouaha LR, Theron A, Thomas D, Tonissen KF, Townson S, Tripathi AK, Trofimov V, Udenze KO, Ullah I, Vallieres C, Vigil E, Vinetz JM, Voong Vinh P, Vu H, Watanabe NA, Weatherby K, White PM, Wilks AF, Winzeler EA, Wojcik E, Wree M, Wu W, Yokoyama N, Zollo PH, Abla N, Blasco B, Burrows J, Laleu B, Leroy D, Spangenberg T, Wells T, Willis PA.

PLoS Pathog. 2016 Jul 28;12(7):e1005763. doi: 10.1371/journal.ppat.1005763. eCollection 2016 Jul.

8.

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.

Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H.

Front Immunol. 2014 May 22;5:233. doi: 10.3389/fimmu.2014.00233. eCollection 2014.

9.

Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties.

Molette J, Routier J, Abla N, Besson D, Bombrun A, Brun R, Burt H, Georgi K, Kaiser M, Nwaka S, Muzerelle M, Scheer A.

ACS Med Chem Lett. 2013 Sep 22;4(11):1037-41. doi: 10.1021/ml400015f. eCollection 2013 Nov 14.

10.

Discovery of a Novel Series of CRTH2 (DP2) Receptor Antagonists Devoid of Carboxylic Acids.

Crosignani S, Jorand-Lebrun C, Campbell G, Prêtre A, Grippi-Vallotton T, Quattropani A, Bouscary-Desforges G, Bombrun A, Missotten M, Humbert Y, Frémaux C, Pâquet M, El Harkani K, Bradshaw CG, Cleva C, Abla N, Daff H, Schott O, Pittet PA, Arrighi JF, Gaudet M, Johnson Z.

ACS Med Chem Lett. 2011 Oct 10;2(12):938-42. doi: 10.1021/ml200223s. eCollection 2011 Dec 8.

11.

Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.

Crosignani S, Prêtre A, Jorand-Lebrun C, Fraboulet G, Seenisamy J, Augustine JK, Missotten M, Humbert Y, Cleva C, Abla N, Daff H, Schott O, Schneider M, Burgat-Charvillon F, Rivron D, Hamernig I, Arrighi JF, Gaudet M, Zimmerli SC, Juillard P, Johnson Z.

J Med Chem. 2011 Oct 27;54(20):7299-317. doi: 10.1021/jm200866y. Epub 2011 Oct 3.

PMID:
21916510
12.

A fast screening strategy for characterizing peptide delivery by transdermal iontophoresis.

Henchoz Y, Abla N, Veuthey JL, Carrupt PA.

J Control Release. 2009 Jul 20;137(2):123-9. doi: 10.1016/j.jconrel.2009.03.018. Epub 2009 Apr 5.

PMID:
19348865
13.

The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.

Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL.

J Pharmacol Exp Ther. 2008 Jun;325(3):859-68. doi: 10.1124/jpet.108.136523. Epub 2008 Mar 25.

14.

Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.

Abla N, Naik A, Guy RH, Kalia YN.

Pharm Res. 2006 Aug;23(8):1842-9.

PMID:
16850271
15.

Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility.

Abla N, Geiser L, Mirgaldi M, Naik A, Veuthey JL, Guy RH, Kalia YN.

J Pharm Sci. 2005 Dec;94(12):2667-75.

PMID:
16258982
16.

Effect of charge and molecular weight on transdermal peptide delivery by iontophoresis.

Abla N, Naik A, Guy RH, Kalia YN.

Pharm Res. 2005 Dec;22(12):2069-78. Epub 2005 Sep 26.

PMID:
16170597
17.

Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin.

Abla N, Naik A, Guy RH, Kalia YN.

J Control Release. 2005 Nov 28;108(2-3):319-30. Epub 2005 Sep 19.

PMID:
16169627

Supplemental Content

Support Center